EcoDrugPlus

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSDORG00000008797
Gene Symbol: CHRM5
4 Cross references
264 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSDORG00000008628
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSDORG00000010785
Gene Symbol: CHRNA7
4 Cross references
249 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSDORG00000007810
Gene Symbol: CHRNB2
4 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSDORG00000029900
Gene Symbol: CHRNB4
3 Cross references
199 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha Polypeptide 4

Ensembl ID : ENSDORG00000023973
Gene Symbol: CHRNA4
1 Cross references
206 Possible Orthologues:

Churchill Domain Containing 1

Ensembl ID : ENSDORG00000009028
Gene Symbol: CHURC1
4 Cross references
211 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSDORG00000023264
Gene Symbol: F2R
4 Cross references
330 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSDORG00000029579
Gene Symbol: F2
4 Cross references
86 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSDORG00000023704
Gene Symbol: F3
4 Cross references
246 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSDORG00000009914
Gene Symbol: F7
4 Cross references
203 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSDORG00000009916
Gene Symbol: F10
3 Cross references
239 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).